Head-to-head · WeighScore
Meto vs Spry
The verdict
Meto takes it — 62/100 to 56.8/100.
Meto grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Meto is an insurance-accepting metabolic telehealth platform offering compounded semaglutide and compounded tirzepatide, prescribed after clinician-ordered lab work.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Meto | Spry |
|---|---|---|
| WeighScore | 62/100 | 56.8/100 |
| Grade | C | C |
| Scorecard rank | #281 | #409 |
| Semaglutide | Not disclosed | $199/mo (starting dose, compounded) |
| Tirzepatide | Not disclosed | $299/mo (starting dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #281 · C
Strengths
- Accepts major insurance (Blue Cross, Anthem, United, Aetna) — most patients pay $0–50 per visit
- Requires lab work before prescribing GLP-1s; addresses root-cause metabolic drivers
- Matches patients with endocrinologists and obesity medicine specialists within minutes
- Offers compounded semaglutide and tirzepatide with board-certified physician oversight
- Handles all prior-auth paperwork; provider location pages exist for all 50 US states
Where it loses points
- Medication pricing fully gated behind quiz — no public cash price for sema or tirz
- Lab panels are a separate out-of-pocket cost ($199–$399) unless covered by insurance
- No LegitScript certification or named compounding pharmacy found on any public page
- Company leadership and clinical team not disclosed publicly
- Self-pay cash pricing exists per site copy but is not published anywhere
Graded #409 · C
Strengths
- Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
- Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
- Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
- No contracts or commitment required
- LegitScript Certified with a public verification link
Where it loses points
- Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
- Intake reviewed by a nurse practitioner, not an MD
- States served not disclosed publicly
- Pharmacy partner not named, and 503A vs 503B designation not specified
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.